Empowered Patient Podcast Pulse Prime Approach to Modulating the Immune System in Fight Against Tumors with Jeffrey Meckler Indaptus Therapeutics
Jeffrey Meckler, CEO of Indaptus Therapeutics, is focused on using their decoy platform to activate the immune system to fight cancer and infections. This approach activates the innate and adaptive pathways in a controlled manner using a short-term pulsed dosing regimen and helps avoid the toxicity issues seen in other immunotherapies. The therapy is cleared from the system quickly, allowing the immune system to be modulated and potentially used with other cancer treatments.
Jeffrey explains, "It's a very uncommon approach because we have, over the last several decades, really had a paradigm for treating cancer in immunotherapy, and that paradigm is turning one or a couple switches in the immune system to help fight the cancer. Again, as I mentioned before, the concept of doing too much, activating too much comes from this idea that you'll hit toxicities and, like I said, cytokine storm or whatever. What we do is go about it in a way that people are coming to. The big talk right now are these VEGF PD-1 bispecific antibodies and what they're actually doing. Part of this is that the VEGF activates innate immune pathways. The PD-1 activates adaptive immune pathways."
"So there's a lot of talk about what's been going on with Summit Therapeutics, and everybody now is doing these VEGF PD-1. We're even broader than that. And more importantly, we're also in a short burst. We call our therapy pulse prime, but it's cleared in the system within a couple of hours. So it does this activation, but instead of keeping the foot on the accelerator the entire time, it lets up. And what we started doing is giving it weekly, and our preclinical models show that weekly administration in combination with other therapies is the most potent approach for us."
#IndaptusTherapeutics #Decoy20 #Biotech #Cancer #CancerResearch #Immunotherapy #LungCancer #BladderCancer #LiverCancer #PancreaticCancer #ColonCancer